The R&D and production base projects of pharmaceutical companies are accelerating, and good news has recently come from companies such as Microchip and Andico

【Pharmaceutical Network Industry Trends】In recent years, with the trend of specialization and high-end development in the pharmaceutical industry, many domestic pharmaceutical companies have accelerated the construction of new production bases with the core of expanding production capacity, upgrading production lines, and deepening industry university research cooperation. Since 2026, several pharmaceutical companies have announced new progress in the construction of their base projects.
 

On January 14th, the main structure of the Chengdu Pengzhou Microchip Original New Drug Manufacturing Base project was fully capped. It is reported that this is the third original new drug manufacturing base of Shenzhen Weixin Biotechnology Co., Ltd. The first and second are located in Pingshan District of Shenzhen and Gaoxin West District of Chengdu, respectively.
 

The first phase of the base focuses on the production of original new drugs, especially for the treatment of type 2 diabetes with siglietazide sodium. After the project is put into operation in 2027, an additional production capacity of 1.2 billion tablets of sitagliptin sodium will be added (including 400 million tablets in the first phase), providing a solid guarantee for product market expansion.
 

On January 13th, it was announced that the isotope drug research and production project of Tianjin Andike Pharmaceutical Co., Ltd. has been successfully completed, and this project with a total investment of about 300 million yuan has officially entered the production preparation stage. It is reported that the completed project focuses on the research and production of radiopharmaceuticals for positive electron emission tomography/computed tomography diagnosis, which belongs to the forefront of precision medicine supported by the state.
 

After the project is put into operation, a complete industrial loop of "research and development production distribution clinical application" will be built, which will not only drive the local aggregation of upstream and downstream industries such as medical imaging and health management, but also promote the overall upgrading of regional medical supporting facilities and service capabilities.
 

On January 6th, it was reported that Zhejiang Huayuan Kexin Pharmaceutical Co., Ltd.'s annual production of 800 million high-end inhalation formulations research and development and intelligent manufacturing base is rapidly advancing according to plan. At present, individual buildings such as office buildings, quality inspection buildings, dormitory buildings, equipment workshops, and storage centers are being constructed simultaneously, and it is expected that five individual buildings will be capped before the Spring Festival.
 

It is understood that the project will be constructed in two phases, with the first phase planned to invest 1.585 billion yuan. The project will adopt intelligent manufacturing technology, purchase advanced equipment such as powder mist and aerosol production lines, and produce innovative drugs of 15 varieties including inhalation solutions, suspensions, and aerosols. After the completion of the project, it will form synergy with the existing industries of vitamin D3, pharmaceuticals, medical devices, etc. of the group, injecting strong impetus into the development of the life and health industry.
 

From the above progress, it can be seen that the current construction of innovative drug bases in China has shown a trend towards focusing on cutting-edge technologies and therapies, as well as strengthening the integration of "research and development production" capabilities. At the same time, it also reflects that the current development and construction of China's innovative pharmaceutical industry is "upgrading in quality", shifting from pursuing "quantity" and "scale" to building high-end industrial capabilities that support source innovation and global competition.
 

In the future, these bases are expected to provide solid physical space and industrial chain support for the incubation and commercialization of more innovative drugs, and promote the synergy of "research and development production clinical" resources in the pharmaceutical industry, further reducing industry costs.
 

　　Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone.